Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination is a topical dermatological formulation primarily developed by Beiersdorf for the treatment of acne-prone skin. It utilizes a multi-modal approach to address the four key factors of acne: hyperkeratosis, seborrhea, microbial colonization, and inflammation. Salicylic acid acts as a keratolytic agent to unclog pores and reduce blemishes; L-carnitine regulates sebum production by promoting fatty acid oxidation within sebocytes; Decanediol (1,2-decanediol) provides targeted antibacterial activity against *Cutibacterium acnes*; and Licochalcone A, a flavonoid derived from licorice root (*Glycyrrhiza inflata*), serves as a potent anti-inflammatory and antioxidant agent to soothe irritation and reduce redness. The formulation is designed to improve skin clarity and texture while minimizing the risk of irritation often associated with intensive acne treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on licochalcone A + decanediol + L-carnitine + salicylic acid.